KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Amortizatization of Intangibles (2016 - 2020)

TherapeuticsMD (TXMD) has disclosed Amortizatization of Intangibles for 11 consecutive years, with $68667.0 as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Amortizatization of Intangibles rose 19.66% year-over-year to $68667.0, compared with a TTM value of $269546.0 through Dec 2020, up 36.41%, and an annual FY2020 reading of $269546.0, up 36.41% over the prior year.
  • Amortizatization of Intangibles was $68667.0 for Q4 2020 at TherapeuticsMD, down from $69976.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $69976.0 in Q3 2020 and bottomed at $11234.0 in Q1 2016.
  • Average Amortizatization of Intangibles over 5 years is $35283.7, with a median of $27963.0 recorded in 2018.
  • The sharpest move saw Amortizatization of Intangibles soared 95.38% in 2019, then increased 19.66% in 2020.
  • Year by year, Amortizatization of Intangibles stood at $15985.0 in 2016, then grew by 20.08% to $19195.0 in 2017, then skyrocketed by 84.17% to $35351.0 in 2018, then surged by 62.33% to $57387.0 in 2019, then rose by 19.66% to $68667.0 in 2020.
  • Business Quant data shows Amortizatization of Intangibles for TXMD at $68667.0 in Q4 2020, $69976.0 in Q3 2020, and $67748.0 in Q2 2020.